セッション詳細
[S-03]シンポジウム03 Toward an International Consensus on MG Treatment
2025年5月21日(水) 9:50 〜 11:50
第07会場(大阪国際会議場12F 特別会議場)
座長：槍澤 公明（総合花巻病院 神経内科）, 村井 弘之（国際医療福祉大学 脳神経内科）
In the treatment of myasthenia gravis, which used to be primarily steroid-oriented, pioneering research from Japan has revealed the benefit of early fast-acting treatment (EFT) and proposed minimal manifestation with prednisolone 5 mg (MM5mg) as the initial therapeutic goal. Although the need for steroid reduction has been recognized globally, treatment approaches vary by country due partially to differences in the availability of non-steroidal immunosuppressive drugs. With the progress of global clinical trials for novel molecular-targeted agents and their subsequent approval in various countries, there is growing momentum for consensus-building on therapeutic guidelines. This symposium will provide an opportunity to discuss international guidance for MG treatment in the era of molecular-targeted drugs with internationally renowned leaders in Japan and abroad.
[S-03-1]Impact of early fast-acting treatment in myasthenia gravis
鵜沢 顕之 (千葉大学医学部附属病院 脳神経内科)
CAREER
2003-2005 Department of Neurology, Chiba University Hospital
2005-2006 Department of Neurology, Chiba Municipal Aoba Hospital
2006-2007 Department of Neurology, Chiba Rosai Hospital
2007-2008 Department of Neurology, Matsudo Municipal Hospital
2008- Department of Neurology, Chiba University Hospital
SPECIALITY
Neuroimmunology (myasthenia gravis; multiple sclerosis; neuromyelitis optica)
Editorial committee member of Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome
AWARDS
2022 Japanese Society for Neuroimmunology, Research and Creation Award
2022 Japanese Society of Neurological Therapeutics, Therapeutic Academic Award
2022 Best Oral Presentation Award, Japanese Society of Neurological Therapeutics
2018 Best Oral Presentation Award, Japanese Society of Neurology
2012 Asian Oceanian Congress of Neurology, Young Investigator Encouragement
2003-2005 Department of Neurology, Chiba University Hospital
2005-2006 Department of Neurology, Chiba Municipal Aoba Hospital
2006-2007 Department of Neurology, Chiba Rosai Hospital
2007-2008 Department of Neurology, Matsudo Municipal Hospital
2008- Department of Neurology, Chiba University Hospital
SPECIALITY
Neuroimmunology (myasthenia gravis; multiple sclerosis; neuromyelitis optica)
Editorial committee member of Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome
AWARDS
2022 Japanese Society for Neuroimmunology, Research and Creation Award
2022 Japanese Society of Neurological Therapeutics, Therapeutic Academic Award
2022 Best Oral Presentation Award, Japanese Society of Neurological Therapeutics
2018 Best Oral Presentation Award, Japanese Society of Neurology
2012 Asian Oceanian Congress of Neurology, Young Investigator Encouragement
[S-03-2]Real-world experience with novel therapeutics in Japan
渡邉 充 (九州大学病院 脳神経内科)
Education:
2017: Ph.D., Kyushu University
2006: M.D., Kyushu University
Professional Experiences:
2019-present: Assistant Professor, Department of Neurology, Kyushu University Hospital
2018-2019: Assistant Professor, Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University
2016-2018: Assistant Professor (Clinical Service), Department of Neurology, Kyushu University Hospital
2012-2016: Clinical Fellow/Medical staff, Department of Neurology, Kyushu University Hospital
2010-2012: Neurological Resident, Department of Neurology, Kitano Hospital
2009-2010: Medical staff, Department of Neurology, Iizuka Hospital
2008-2009: Medical staff, Department of Neurology, Kyushu University Hospital
2006-2008: Clinical Resident, Kyushu Kosei-Nenkin Hospital
Others:
Certified Doctor of the Japanese Society for Neuroimmunology
Systematic review member of clinical practice guidelines for MS and NMOSD 2023 in Japan
2017: Ph.D., Kyushu University
2006: M.D., Kyushu University
Professional Experiences:
2019-present: Assistant Professor, Department of Neurology, Kyushu University Hospital
2018-2019: Assistant Professor, Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University
2016-2018: Assistant Professor (Clinical Service), Department of Neurology, Kyushu University Hospital
2012-2016: Clinical Fellow/Medical staff, Department of Neurology, Kyushu University Hospital
2010-2012: Neurological Resident, Department of Neurology, Kitano Hospital
2009-2010: Medical staff, Department of Neurology, Iizuka Hospital
2008-2009: Medical staff, Department of Neurology, Kyushu University Hospital
2006-2008: Clinical Resident, Kyushu Kosei-Nenkin Hospital
Others:
Certified Doctor of the Japanese Society for Neuroimmunology
Systematic review member of clinical practice guidelines for MS and NMOSD 2023 in Japan
[S-03-3]Chinese Evidence on Biologic Targeted Therapy for Myasthenia Gravis Patients
Chongbo Zhao (Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai)
Zhao Chongbo is the chief physician, professor, and deputy director of the Department of Neurology at Huashan Hospital, Fudan University. He serves as a committee member of the Chinese Society of Neurology, an executive member of the Asian Oceanian Myology Center, and a member of the World Myology Society. In 2002, he graduated from the Shanghai Medical College of Fudan University, earning a doctorate in clinical neurology. He conducted postdoctoral research at the Barrow Neurological Institute in Phoenix, Arizona, USA, from 2006 to 2007. Currently, he focuses on clinical research related to myasthenia gravis,neuropathy and myopathy.
[S-03-4]Formulating International Consensus Guidance for Myasthenia Gravis
Pushpa Narayanaswami1,2 (1.Beth Israel Deaconess Medical Center, 2.Harvard Medical School)
Pushpa Narayanaswami is Professor of Clinical Neurology at Harvard Medical School and Vice-Chair of Clinical Operations, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA. She is a fellow of the American Academy of Neurology (AAN). She has authored/co-authored several peer-reviewed articles, invited reviews, editorials, clinical practice guidelines, quality measures, book chapters and edited a book, “Principles and Practice of the Muscular Dystrophies”. She has received federal research funding from the Agency for Healthcare Research and Quality (AHRQ), Patient Centered Outcomes Research Institute (PCORI) and National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). She serves as an associate editor for Muscle and Nerve® and the Associate Editor, Classification of Evidence, for Neurology®. She co-chairs the Quality Improvement and Patient Safety Committee of the American Association of Neuromuscular and Electrodiagnostic Medicine.
In her clinical practice she manages neuromuscular conditions, with special emphasis on myasthenia gravis, myopathies and muscular dystrophies. Her research includes clinical trials of new treatments for myasthenia gravis and observational studies of the effectiveness of treatments in clinical practice. She is a methodologist for several guidelines in development. Her work seeks to incorporate research with advocacy and healthcare policy to improve patient care.
In her clinical practice she manages neuromuscular conditions, with special emphasis on myasthenia gravis, myopathies and muscular dystrophies. Her research includes clinical trials of new treatments for myasthenia gravis and observational studies of the effectiveness of treatments in clinical practice. She is a methodologist for several guidelines in development. Her work seeks to incorporate research with advocacy and healthcare policy to improve patient care.